Clinical Trials Sponsored by Forest Laboratories

Total 9283 results

Forest Laboratories

Completed

A Lactation Study in Women Who Are Breastfeeding or Pumping and Are Receiving Linaclotide Therapeutically (LIN-PK-01)

Irritable Bowel Syndrome | Constipation | Breast Feeding

United States
Forest Laboratories

Completed

Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder

Generalized Anxiety Disorder

United States
Forest Laboratories

Completed

Study To Assess Efficacy and Safety of Oglemilast in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States
Forest Laboratories

Completed

Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine

Autistic Disorder | Autism | Autism Spectrum Disorders | Asperger Syndrome | Asperger's Disorder | Pervasive Developmental Disorder - Not Otherwise Specified (PDD-NOS)

United States, Belgium, Colombia, Estonia, France, Hungary, Iceland, Italy, Korea, Republic of, New Zealand, Poland, Serbia, South Africa, Spain, Ukraine
Forest Laboratories

Completed

Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Participants With Bipolar I Disorder

Depression | Bipolar Disorder

United States, Bulgaria, Serbia, Ukraine, Croatia, Romania, Puerto Rico, Slovakia
Forest Laboratories

Completed

Study on the Efficacy, Safety, and Tolerability of Cariprazine Relative to Placebo in Participants With Bipolar I Depression

Depression | Bipolar Disorder

United States, Bulgaria, Poland, Puerto Rico, Lithuania, Estonia
Forest Laboratories

Completed

A Multicenter, Relapse Prevention Study With Levomilnacipran Extended Release (ER) in Participants With Major Depressive Disorder

Depressive Disorder, Major

United States
Forest Laboratories

Completed

Diafert for Embryo Selection and Fertility Improvement (DESTINy)

Infertility

Belgium
Forest Laboratories

Completed

Safety and Efficacy Study of ULTRASE® MT20 in Participants With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (PI)

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States
Forest Laboratories

Completed

Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections (cSSSI)

Bacterial Infections

Argentina, Chile, Mexico, Russian Federation, United States, Poland, Germany, Brazil, Peru, Romania, Ukraine
Forest Laboratories

Completed

Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia (CAP)

Bacterial Pneumonia

United States, Argentina, Austria, Bulgaria, Chile, Germany, Hungary, India, Latvia, Mexico, Peru, Poland, Romania, Russian Federation, Ukraine
Forest Laboratories

Completed

Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections

Bacterial Infections

United States, Chile, Latvia, Poland, Russian Federation, Argentina, Mexico, Austria, Brazil, Germany, Ukraine, United Kingdom
Forest Laboratories

Completed

Bioavailability Study of Anti Nausea Medication With and Without Food (EUR-1025) (ODO-P8-689)

Nausea
Forest Laboratories

Terminated

Preliminary Efficacy and Tolerability of NCX-1000 After Repeated Oral Doses in Patients With Elevated Portal Pressure

Portal Hypertension

Spain
Forest Laboratories

Withdrawn

Safety, Efficacy of Pylera BID Dosing in Eradication of H. Pylori

Helicobacter Pylori Infection

United States, Canada
Forest Laboratories

Completed

Effect of Itopride, on Symptoms of Functional Dyspepsia, Such as Indigestion, Bloating, Inability to Finish a Meal

Dyspepsia

Canada
Forest Laboratories

Terminated

A Study to Examine MPI SPECT Imaging With BMS068645 and Adenosine Compared to Coronary Angiography

Ischemic Heart Disease | Heart Disease

United States
Forest Laboratories

Completed

Long Term Safety of 125 mg Per Day of Oral Azimilide in Patients With Implantable Cardioverter Defibrillator (ICDs)

Arrhythmias

United States, Canada, Poland, Germany, Spain, Belgium, France
Forest Laboratories

Terminated

A Phase II Optimization Study of BMS068645 and Sestamibi Planar Imaging

Cardiovascular Disease | Ischemic Heart Disease

United States
Forest Laboratories

Completed

Safety and Efficacy of Vilazodone in Major Depressive Disorder (VLZ-MD-01)

Major Depressive Disorder

United States
Forest Laboratories

Completed

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder

Major Depressive Disorder

United States
Forest Laboratories

Completed

A Study to Evaluate the Mode of Administration and Safety of EUR-1008 (APT-1008) in Infants 1 to 12 Months of Age

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States
Forest Laboratories

Completed

Safety, Efficacy, and Tolerability of Vilazodone in Major Depressive Disorder

Major Depressive Disorder

United States
Forest Laboratories

Completed

Comparative Study of Coadministered Ceftaroline Fosamil and NXL104 vs. Intravenous Doripenem in Adult Subjects With Complicated Urinary Tract Infections

Urinary Tract Infections

Russian Federation, Bulgaria, Poland, Germany, United States, Lebanon, Turkey
Forest Laboratories

Completed

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder

Major Depressive Disorder

United States
Forest Laboratories

Completed

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder

Major Depressive Disorder

United States
Forest Laboratories

Completed

Study of the Efficacy and Safety of Nebivolol in Younger Patients (18 - 54 Years)

Hypertension

United States
Forest Laboratories

Withdrawn

Safety and Efficacy Study of Ceftaroline in Elderly Subjects With Community-Acquired Bacterial Pneumonia

Community-Acquired Bacterial Pneumonia (CABP)
Forest Laboratories

Completed

Safety Study of F2695 SR in Major Depressive Disorder (LVM-MD-04)

Major Depressive Disorder

United States
Forest Laboratories

Completed

Efficacy and Safety Study to Evaluate Combination Therapy With Nebivolol and Lisinopril vs. Placebo and Monotherapy in Patients With Stage 2 Diastolic Hypertension

Stage 2 Diastolic Hypertension

United States, Puerto Rico
Forest Laboratories

Completed

The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's Disease

Alzheimer's Disease

United States
Forest Laboratories

Completed

The Safety and Efficacy of Dexloxiglumide for the Relief of Symptoms of Functional Dyspepsia.

Dyspepsia

United States
Forest Laboratories

Completed

An Evaluation of the Safety and Efficacy of Memantine in Agitated Patients With Moderate to Severe Alzheimer's Disease

Alzheimer's Disease

United States
Forest Laboratories

Completed

Efficacy and Safety Evaluation of Azimilide or Sotalol vs Placebo for Treatment of Patients With Atrial Fibrillation.

Atrial Fibrillation

Germany, France, Belgium, Hungary, Italy, Netherlands, Poland, Russian Federation, Spain
Forest Laboratories

Completed

Efficacy and Safety of Azimilide for the Treatment of Patients With Atrial Fibrillation

Atrial Fibrillation

United States, Canada
Forest Laboratories

Completed

Study of the Glycemic Effects of Nebivolol Compared With Metoprolol and HCTZ in Diabetic Hypertensive Patients

Hypertension | Type 2 Diabetes Mellitus

United States, Puerto Rico
Forest Laboratories

Completed

Randomized, Double-Blind, Placebo Controlled Study of Vilazodone's Efficacy, Safety, and Biomarkers of Response in Major Depressive Disorder (MDD)

Major Depressive Disorder

United States
Forest Laboratories

Completed

Escitalopram in Adult Patients With Major Depressive Disorder

Major Depressive Disorder

United States
Forest Laboratories

Completed

Effect of Memantine on Functional Communication in Patients With Alzheimer's Disease

Alzheimer's Disease

Australia, New Zealand, South Africa
Forest Laboratories
Mylan Laboratories

Terminated

Study to Evaluate Symptoms in Patients Treated With Nebivolol or Metoprolol Extended-release (ER) for Hypertension

Hypertension

United States
Forest Laboratories

Completed

The Blood Pressure and Metabolic Effects of Nebivolol in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose

Hypertension

United States
Forest Laboratories

Completed

Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder

Depression | Major Depressive Disorder

United States, Canada
Forest Laboratories

Completed

Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder (VLZ-MD-05)

Generalized Anxiety Disorder

United States
Forest Laboratories

Completed

A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD)

Major Depressive Disorder

United States
Forest Laboratories

Completed

Diafert for Embryo Selection and Fertility Improvement (DESTINy) (DESTINy)

Infertility

Hungary
Forest Laboratories

Terminated

Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer

Neoplasms | Febrile Neutropenia

United States
Forest Laboratories

Completed

PR-018: An Open-Label, Safety Extension of Study PR-011

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States
Forest Laboratories

Completed

Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI)

Cystic Fibrosis | Pancreatic Insufficiency

United States
Forest Laboratories

Completed

Study of Pancreatic Enzyme Product in Pediatric Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States
Forest Laboratories

Completed

Safety and Efficacy Study of Viokase® 16 for the Correction of Steatorrhea

Chronic Pancreatitis | Exocrine Pancreatic Insufficiency | Pancreatectomy

Canada, United States, Poland, Slovakia

3

Subscribe